BPG致力于知识的发现和传播
临床研究
©The Author(s) 2025.
世界华人消化杂志. 2025-09-28; 33(9): 716-724
在线出版 2025-09-28. doi: 10.11569/wcjd.v33.i9.716
表5 影响乌司奴单抗治疗克罗恩病治疗应答率的单因素分析[n(%)]
因素完成16 wk治疗
完成52 wk治疗
乌司奴临床应答组(n = 185)乌司奴临床不应答组(n = 85)t/χ2P乌司奴临床应答组(n = 242)乌司奴临床不应答组(n = 28)t/χ2P
性别94(50.81)48(56.47)0.7480.387126(52.07)16(57.24)0.5390.463
91(49.19)37(43.53)120(47.93)12(42.76)
发病年龄(岁, mean±SD)31.92±7.9931.28±8.580.5970.55131.66±6.2331.45±6.440.1680.866
BMI(kg/m2, mean±SD)20.52±1.8720.55±1.81-0.1240.90221.12±1.4321.09±1.310.1060.916
病程(年, mean±SD)6.31±2.96.26±2.870.1320.8956.29±2.716.31±2.700.0370.971
CDAI评分(分, mean±SD)364.28±86.47356.44±79.650.7090.479370.18±76.71361.42±73.120.5750.566
吸烟65(35.14)21(24.71)2.9180.08878(32.23)8(28.57)0.3170.573
120(64.86)64(75.29)164(67.77)20(71.43)
饮酒40(21.62)13(15.29)1.4780.22449(20.25)4(14.29)0.6090.435
145(78.38)72(84.71)193(79.75)24(75.71)
内镜下黏膜病变程度中度121(65.41)61(71.76)1.0720.300148(61.16)20(71.43)2.3600.124
重度64(34.59)24(28.24)94(38.84)8(28.57)
病变位置回肠末端37(20.00)15(17.65)0.2080.90148(19.83)4(14.29)1.6720.344
结肠42(22.70)20(23.53)54(22.31)8(28.57)
回结肠106(57.30)50(58.82)140(57.85)16(57.24)
疾病类型非狭窄非穿透型94(50.81)9(10.59)75.5190.00099(40.91)4(14.29)25.5160.000
狭窄型75(40.54)31(36.47)96(39.67)10(35.71)
穿透型16(8.65)45(52.94)47(19.42)14(50.00)
肛周累及11(5.95)29(34.12)36.6260.0006(2.48)8(28.57)26.5160.000
174(94.05)56(65.88)136(97.52)20(71.43)
既往糖皮质激素/免疫抑制剂治疗69(37.3)39(45.88)1.7890.18194(38.84)14(50.00)2.5220.112
116(62.7)46(54.12)148(61.16)14(50.00)
既往TNF-α抑制剂治疗71(38.38)62(72.94)27.8360.00090(37.19)20(71.43)23.6230.000
114(61.62)23(27.06)152(62.81)8(28.57)
肠道手术史26(14.05)17(20.00)1.5380.21537(15.29)6(21.43)1.2580.262
159(85.95)68(80.00)205(84.71)22(78.57)
合并高血压25(13.51)8(9.41)0.9130.33931(12.81)2(7.14)1.7900.180
160(86.49)77(90.59)211(87.19)26(92.86)
合并糖尿病9(4.86)5(5.88)0.1230.72612(4.96)2(7.14)0.4180.518
176(95.14)80(94.12)230(95.04)26(92.86)

引文著录: 王秀芳, 王银娟, 王芬芬, 倪栋琼. 影响维得利珠单抗与乌司奴单抗治疗中重度活动期克罗恩病治疗应答的多因素分析. 世界华人消化杂志 2025; 33(9): 716-724
写信给帮助平台